Since 2015, the genericized Parkinson’s disease (PD) market has witnessed the launch of nearly a dozen unique brands (e.g., Inbrija, Kynmobi, Nourianz), and several more are on the horizon,…
Epilepsy, which afflicts approximately 4.7 million people in the major pharmaceutical markets under study according to Clarivate epidemiology, is a heterogeneous condition requiring individualized…
Migraine, which afflicts approximately 34 million people in the major pharmaceutical markets according to Clarivate epidemiology, is a heterogeneous condition requiring individualized treatment…
The increasingly crowded RA market boasts many targeted agents representing several different drug classes, including blockbuster TNF-α inhibitors, five non-TNF-α biologics (including the second…
DRG Epidemiology's coverage of acute coronary syndrome comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the incidence and prevalence…
DS is a rare, severe, pediatric-onset genetic epileptic encephalopathy characterized by developmental delay and multiple types of difficult-to-treat seizures. In particular, convulsive seizures…
Cell therapy uses viable healthy cells to replace, expand, and/or enhance a population of cells in order to achieve a therapeutic effect against a disease. The cell therapy field is rapidly…
Clarivate Epidemiology's coverage of ACS comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the incidence and prevalence of acute…
Clarivate’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key acute coronary syndrome patient populations covering 171 countries…
Sjögren’s syndrome (SS) is a progressive autoimmune disease characterized by chronic inflammation and lymphocytic infiltration of the exocrine glands that may occur alone (primary SS) or with a…
The Emerging Biosimilars Landscape offers extensive coverage of the global biosimilars development landscape. We track over 600 currently available and novel biosimilar products, detailing…
The development and commercialization of biosimilars require a significant investment in capital, resources, and time. Biosimilar developers must ensure that they are equipped with the necessary…